@Article{ecn.2023.0491,
AUTHOR = {Mohammad Reza Haghshenas, Zahra Shiravani, Mohammad Samare-Najaf, Soolmaz Khansalar, Seyed Ali Razavinasab, Abbas Ghaderi, Navid Jamali},
TITLE = {Clinical significance of IL-37 serum level and polymorphism in  patients with endometrial cancer},
JOURNAL = {European Cytokine Network},
VOLUME = {34},
YEAR = {2023},
NUMBER = {4},
PAGES = {63--69},
URL = {http://www.techscience.com/ECN/v34n4/64883},
ISSN = {1952-4005},
ABSTRACT = {<i>Background:</i> Endometrial cancer (EC) is recognized as the second most common type of cancer among women. Interleukin-37 (IL-37) is a recently discovered member of the IL-1 cytokine family characterized by its anti-inflammatory properties, which are believed to have both anti-tumour and tumorigenic effects. However, the precise role of IL-37 in the development of EC remains largely unknown. <i>Objective:</i> In the current study, we aimed to explore genotype and allele frequencies of the IL-37 gene (rs4241122) and measure IL-37 protein levels in patients with EC, with a view to determining the clinical significance in these patients. <i>Methods:</i> A total of 105 patients with confirmed EC and 105 healthy controls, aged 31-73, participated in the study. IL-37 serum levels were investigated using an ELISA method, while the frequency of genotypes and alleles of the IL-37 gene was determined using the ARMS-PCR method. <i>Results:</i> The findings demonstrate a significant increase in IL-37 serum levels in EC patients compared to controls (p<0.0001). Moreover, higher levels of IL-37 were strongly associated with unfavourable indices, such as EC grade III, poorly differentiated tumours, and regional spread of tumour cells (p<0.05). In contrast, genotyping of the IL-37 gene revealed no significant difference between the two groups, and there was no association between IL-37 genotype and IL-37 protein level or clinicopathological characteristics (p>0.05). <i>Conclusion:</i> The results of this study suggest that elevated serum levels of may contribute to tumour progression, probably through its immune suppressive activity. Clinically, IL-37 may serve as a promising factor and/or therapeutic target for EC management, although, further studies are warranted.},
DOI = {10.1684/ ecn.2023.0491}
}